RallyBio Corp (NASDAQ: RYBO) has announced that the employment of Jonathan Lieber, its Chief Financial Officer (CFO), will terminate upon the closing of the company’s business combination with Avenzo Acquisition Corp, a special purpose acquisition company (SPAC). The information was disclosed in <a href="https://www.google.com/goto?url=CAESiwEB6zswFW8iN8tU38V_H4vf0DKOVra0gY7AUiId1fpSYymFZ9P5VKptHL5Tt61X12AjVdsLGuMUumSzOfPOq5M9i2gLBonoW9Xax67_QdBJcrCq7v1rkfNNR9SrFNDrh07Qc8E5dgoATYH7RWUO8tqwZJXyJ4CNXT5J3mSxsBU-JZxPKDOCp8RB__B8">a recent SEC filing</a>.Lieber’s employment agreement, dated February 1, 2023, outlines the terms of his role as CFO and Treasurer of RallyBio, LLC and its parent company, <a href="https://www.google.com/goto?url=CAESiwEB6zswFW8iN8tU38V_H4vf0DKOVra0gY7AUiId1fpSYymFZ9P5VKptHL5Tt61X12AjVdsLGuMUumSzOfPOq5M9i2gLBonoW9Xax67_QdBJcrCq7v1rkfNNR9SrFNDrh07Qc8E5dgoATYH7RWUO8tqwZJXyJ4CNXT5J3mSxsBU-JZxPKDOCp8RB__B8">Rallybio Corporation</a>. The agreement includes provisions for base salary, annual bonuses, benefits, and conditions for termination. Under the terms of the agreement, Lieber’s employment is subject to termination without cause or for cause, with <a href="https://www.google.com/goto?url=CAESiwEB6zswFW8iN8tU38V_H4vf0DKOVra0gY7AUiId1fpSYymFZ9P5VKptHL5Tt61X12AjVdsLGuMUumSzOfPOq5M9i2gLBonoW9Xax67_QdBJcrCq7v1rkfNNR9SrFNDrh07Qc8E5dgoATYH7RWUO8tqwZJXyJ4CNXT5J3mSxsBU-JZxPKDOCp8RB__B8">specific severance and continuation benefits</a> depending on the nature of the termination.The filing indicates that Lieber’s employment will terminate as part of the business combination process, which is expected to result in a change in control of the company. In such cases, the agreement provides for <a href="https://www.google.com/goto?url=CAESiwEB6zswFW8iN8tU38V_H4vf0DKOVra0gY7AUiId1fpSYymFZ9P5VKptHL5Tt61X12AjVdsLGuMUumSzOfPOq5M9i2gLBonoW9Xax67_QdBJcrCq7v1rkfNNR9SrFNDrh07Qc8E5dgoATYH7RWUO8tqwZJXyJ4CNXT5J3mSxsBU-JZxPKDOCp8RB__B8">enhanced severance benefits</a>, including a multiple of base salary and target annual bonus, as well as continued health coverage for a specified period.The termination of Lieber’s employment is not indicative of any performance issues or disagreements, as the filing does not suggest any cause for termination. Instead, it is a procedural step tied to the anticipated closing of the business combination with Avenzo. Investors are advised to monitor further SEC filings for updates on the transaction and its implications for RallyBio’s corporate structure and leadership.<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-1d1cd4a6e94db002.png" alt="RallyBio Corp - CFO Jonathan Lieber's employment to terminate upon closing of Avenzo business combination - SEC filing">

Rallybio

RallyBio Corp - CFO Jonathan Lieber's employment to terminate upon closing of Avenzo business combination - SEC filing

RallyBio Corporation (NASDAQ: RLYB) has announced that Jonathan I. Lieber will continue to serve as Chief Financial Officer (CFO) and principal financial officer following the company’s pending merger with Avenzo Therapeutics, Inc. The transition is outlined in <a href="https://www.google.com/goto?url=CAESiAEB6zswFTEo-EzortgNCDsv784mRTVvTAnTXrSSLKbRVpsCw8IA5wrKOtYpqg7fBEvmqsr9fHBILcGhogNFdjsXkgNG2SDWoTGPM0ZoUskDZhWDXiRVmxRvd0JFNizzm_24awCfg3NTca2SWObgdxqsJPpp9ROiP8bayEpS8AW4TJe38Gqfl6Mp">recent SEC filing under Form 8-K</a>, dated May 31, 2026.Under the terms of the merger agreement, Avenzo will become a wholly owned subsidiary of RallyBio, with the combined entity expected to operate under the name “Avenzo Therapeutics, Inc.” Post-merger, Lieber will retain his role as CFO and Chief Business Officer, alongside other key leadership positions from Avenzo, including <a href="https://www.google.com/goto?url=CAESiAEB6zswFTEo-EzortgNCDsv784mRTVvTAnTXrSSLKbRVpsCw8IA5wrKOtYpqg7fBEvmqsr9fHBILcGhogNFdjsXkgNG2SDWoTGPM0ZoUskDZhWDXiRVmxRvd0JFNizzm_24awCfg3NTca2SWObgdxqsJPpp9ROiP8bayEpS8AW4TJe38Gqfl6Mp">Athena Countouriotis, M.D., Chair, President</a>, and CEO.The merger is subject to customary closing conditions, including shareholder approvals and regulatory clearances. Upon completion, the combined company will issue shares of RallyBio Common Stock to Avenzo shareholders and investors participating in the Concurrent Financing, which is expected to <a href="https://www.google.com/goto?url=CAESiAEB6zswFTEo-EzortgNCDsv784mRTVvTAnTXrSSLKbRVpsCw8IA5wrKOtYpqg7fBEvmqsr9fHBILcGhogNFdjsXkgNG2SDWoTGPM0ZoUskDZhWDXiRVmxRvd0JFNizzm_24awCfg3NTca2SWObgdxqsJPpp9ROiP8bayEpS8AW4TJe38Gqfl6Mp">raise $215.0 million</a>.Lieber’s continued leadership is part of a broader strategic alignment between RallyBio and Avenzo, with both companies emphasizing operational continuity and financial stability during the transition. The SEC filing also notes that <a href="https://www.google.com/goto?url=CAESiAEB6zswFTEo-EzortgNCDsv784mRTVvTAnTXrSSLKbRVpsCw8IA5wrKOtYpqg7fBEvmqsr9fHBILcGhogNFdjsXkgNG2SDWoTGPM0ZoUskDZhWDXiRVmxRvd0JFNizzm_24awCfg3NTca2SWObgdxqsJPpp9ROiP8bayEpS8AW4TJe38Gqfl6Mp">Lieber amended his employment agreement</a> to reflect the change in control resulting from the merger.Investors are encouraged to review the Form S-4 and related proxy materials, which will provide further details on the merger structure, shareholder approvals, and financial implications.<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-1d1cd49e924db002.png" alt="RallyBio Corp - Jonathan Lieber to remain as RallyBio CFO and principal financial officer after transition - SEC filing">

RallyBio Corp - Jonathan Lieber to remain as RallyBio CFO and principal financial officer after transition - SEC filing

RallyBio Corp has announced that Jonathan Lieber, the company’s chief financial officer, will transition to part-time employment effective September 15, 2026[1]. The change was disclosed in a recent SEC filing, which noted that Lieber will continue to serve in a reduced capacity, though the specific nature of his responsibilities has not been detailed. The company did not provide further information regarding the transition, including whether a successor will be appointed or how the shift will impact day-to-day financial operations. Investors are likely to monitor the situation for any potential implications on the company’s financial reporting and governance structure. The announcement comes amid ongoing developments in RallyBio’s business strategy and operations. No immediate impact on financial performance was indicated in the filing.<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-1d1cd48d258db002.png" alt="RallyBio Corp - On Sept 8, CFO Jonathan Lieber to transition to part-time employment effective Sept 15, 2026 - SEC filing">

RallyBio Corp - On Sept 8, CFO Jonathan Lieber to transition to part-time employment effective Sept 15, 2026 - SEC filing

According to the 15-minute chart of Rallybio, the Moving Average Convergence Divergence (MACD) indicator has crossed below its signal line, known as a "Death Cross," and the Bollinger Bands have begun to narrow, as of August 24, 2026 at 15:00. This suggests that the stock price has the potential to continue declining, with decreasing volatility.On August 24, 2026 at 15:00, the 15-minute chart of Rallybio (RLAY) showed a notable technical development: the Moving Average Convergence Divergence (MACD) indicator crossed below its signal line, forming what traders refer to as a "Death Cross." This crossover is often interpreted as a bearish signal, indicating <a href="https://www.google.com/goto?url=CAEStQEB6zswFZC3fGAqDoq5y_bCzRDqiQObcKKDiqXXQxKRNyQXb81h319Av2wGNYClsvP7kfdrX7E-B7R_cAcAWgFtcczXCGIhqVx5pco85ZD5rs4jkefVUpLclOH8VC2EP4cvRDHDcFRLx-im0ufnvsISRzq-e1rtMOiloA4GseoDeADG_K9eQ52kx3jLBKmtirSF3v2CNIb2BYcJxDrL-C4wCVkN-11XTH4JOn8IbkfHUJVnFlSS">potential downward momentum</a> in the stock price.Simultaneously, the Bollinger Bands for Rallybio began to narrow, suggesting a reduction in volatility and the possibility of a consolidation phase or a potential breakout in either direction. Narrowing bands, often referred to as a "Bollinger Band squeeze," can precede a significant price move, though <a href="https://www.google.com/goto?url=CAEStQEB6zswFZC3fGAqDoq5y_bCzRDqiQObcKKDiqXXQxKRNyQXb81h319Av2wGNYClsvP7kfdrX7E-B7R_cAcAWgFtcczXCGIhqVx5pco85ZD5rs4jkefVUpLclOH8VC2EP4cvRDHDcFRLx-im0ufnvsISRzq-e1rtMOiloA4GseoDeADG_K9eQ52kx3jLBKmtirSF3v2CNIb2BYcJxDrL-C4wCVkN-11XTH4JOn8IbkfHUJVnFlSS">the direction is not predetermined</a> and requires further price confirmation.Taken together, these indicators suggest Rallybio may be entering a period of increased bearish pressure. The Death Cross in the MACD and the narrowing Bollinger Bands imply that Rallybio’s price could continue to decline in the near term, particularly if the bands eventually expand again with downward bias. However, traders should remain cautious, as technical indicators are not infallible and should be used in conjunction with broader market context, volume analysis, and fundamental factors.As always, investors are advised to conduct further analysis and consider upcoming company-specific events before making any trading decisions.

Rallybio's 15min chart sees MACD death cross, Bollinger Bands narrowing.

Rallybio's 15-minute chart has exhibited a KDJ Death Cross and a Bearish Marubozu pattern on August 24th at 14:45. This indicates a shift in momentum towards the downside and a potential decrease in stock price. Sellers currently dominate the market, and it is likely that the bearish momentum will persist.On August 24th at 14:45, Rallybio's 15-minute chart displayed two significant technical signals: a KDJ Death Cross and a Bearish Marubozu candlestick pattern. These developments suggest a notable shift in market momentum toward the downside. The KDJ Death Cross occurs when the K line crosses below the D line in the overbought region, signaling <a href="https://www.futuhk.com/en/blog/detail-kdj-9-241091014">a potential sell-off</a> and a weakening of bullish momentum. Simultaneously, the Bearish Marubozu pattern, characterized by a candle with no upper or lower shadow and a long real body, indicates <a href="https://groww.in/p/marubozu-candlestick-pattern">strong selling pressure</a> and a lack of buyer participation.The Bearish Marubozu pattern is particularly telling in this context, as it reflects a session where the price opened near its high and closed near its low, with no retracement in between. This pattern is often interpreted as <a href="https://groww.in/p/marubozu-candlestick-pattern">dominance by sellers</a> and a potential continuation of the downward trend. When combined with the KDJ Death Cross, the signals reinforce the likelihood of a bearish continuation in the near term.Traders and investors should be mindful of these signals as they may indicate a short-term reversal or a continuation of the prevailing downtrend. While these patterns do not guarantee future price movements, they serve as useful tools for identifying potential turning points and adjusting trading strategies accordingly. As with any technical analysis, it is advisable to <a href="https://www.futuhk.com/en/blog/detail-kdj-9-241091014">corroborate these signals</a> with additional indicators or market context to make well-informed decisions.

RLYB News